AJJ Medtech Holdings Limited, a leader in healthcare technology, has announced a significant four-year supply contract worth approximately S$3m with a network of Singapore healthcare institutions. The contract, commencing on 1 June 2026, involves the provision of biodegradable medical consumables, aligning with the company’s long-term sustainability strategy.
The agreement, which includes an initial two-year term with an option to extend for another two years, strengthens AJJ Medtech’s position within Singapore’s institutional healthcare ecosystem. This contract is part of a series of institutional tenders recently secured by AJJ Healthcare, a wholly owned subsidiary of AJJ Medtech. With these agreements, the group’s total contracted institutional revenue pipeline now exceeds S$8m.
The focus on biodegradable consumables supports healthcare institutions in adopting environmentally responsible procurement practices. According to William Ong, CEO of AJJ Healthcare, the partnership marks “tangible progress in our ESG-led growth,” helping healthcare partners transition from conventional plastics to biodegradable alternatives.
The contract is expected to avoid more than 600 tonnes of fossil-based CO₂ emissions annually, equivalent to removing over 100 passenger vehicles from the road each year. This aligns with AJJ Medtech’s broader Environmental, Social, and Governance (ESG) commitments.
Whilst the contract is not anticipated to materially impact the company’s Net Tangible Assets or Earnings Per Share for the current financial year, it is expected to contribute positively to the group’s financial performance over the contract’s duration. AJJ Medtech continues to expand its portfolio, including higher-value healthcare solutions such as robotics and intelligent applications, further solidifying its role as a sustainable healthcare solutions provider.
